Anti-p66shc Antibody, clone BG8

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Quality Control Testing

Evaluated by Western Blotting in NIH3T3 cell lysate.

Western Blotting Analysis: A 1:500 dilution of this antibody detected SHC-transforming protein 1 in NIH3T3 cell lysate.

Tested Applications

Immunofluorescence Analysis: A representative lot detected p66shc 1 in Immunofluorescence application (Orsini, F., et al. (2004). J Biol Chem. 279(24): 25689-95).

Immunocytochemistry Analysis: A representative lot detected p66shc in Immunocytochemistry application (Orsini, F., et al. (2004). J Biol Chem. 279(24): 25689-95).

Western Blotting Analysis: A representative lot detected p66shc in Western Blotting application (Orsini, F., et al. (2004). J Biol Chem. 279(24): 25689-95); Su, K.G., et al. (2012). Eur J Neurosci. 35(4):562-71).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone BG8 is a mouse monoclonal antibody that detects p66Shc. It was generated in p66Shc-/- mice. It targets an epitope within the N-terminal region.

SHC-transforming protein 1 (UniProt: P29353; also known as SHC-transforming protein 3, SHC-transforming protein A, Src homology 2 domain-containing-transforming protein C1, SH2 domain protein C1) is encoded by the SHC1 (also known as SHC, SHCA) gene (Gene ID: 6464) in human. p66Shc is a splice variant of p52Shc/p46Shc with a typical domain organization that is shared by all members of the Shc family of adaptor proteins. It has a phosphotyrosine binding domain, a collagen homology 1 region, and an SH2 domain. p66Shc is shown to be a downstream target of p53 and activated p53 induces its up-regulation by increasing its stability. p66Shc is suggested to be a genetic determinant of aging in mammals as its homozygous deletion is reported to delay senescence and prolong life span in mice. It regulates the mitochondrial pathway of apoptosis by inducing mitochondrial damage after dissociation from an inhibitory protein complex. Under conditions of excessive reactive oxygen species (ROS), p66Shc is phosphorylated on serine 36 by protein kinase C and is targeted to the mitochondrial intermembrane space where it serves as a redox enzyme by oxidizing cytochrome c and reducing oxygen to form ROS. In the absence of p66Shc, release of cytochrome c from mitochondria is impaired and apoptosome can only be activated if purified cytochrome c is supplied. p66Shc induces the collapse of the mitochondrial trans-membrane potential after oxidative stress. p66Shc is also shown to have a neuroprotective role in a murine model of multiple sclerosis. p66Shc knockout (p66-KO) mice develop typical signs of experimental autoimmune encephalomyelitis (EAE). (Ref.: Su, KG., et al. (2012). Eur. J. Neurosci. 35; 562-571; Orsini, F., et al. (2004). J. Biol. Chem. 279(24); 25689-25695).

GST-tagged recombinant fragment corresponding to the first 110 amino acids from the N-terminal region of human SHC-transforming protein 1 (p66Shc).

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.